marketwatch.com
May 20, 2008
TEL AVIV (MarketWatch) -- BioAlliance Pharma SA, the Paris drugmaker focused on infections arising from cancer and HIV, said it acquired the rights to market ondansetron oral spray in Europe from NovaDel Pharma Inc., the Flemington, N.J., drugmaker. The spray prevents nausea and vomiting in...
[read full story]